Allogene Therapeutics (ALLO) Other Non Operating Income (2018 - 2026)

Allogene Therapeutics (ALLO) has 9 years of Other Non Operating Income data on file, last reported at $212000.0 in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 130.43% year-over-year to $212000.0; the trailing twelve-month figure through Mar 2026 stood at $335000.0 (up 111.56% YoY), and the FY2025 full-year result was $215000.0, up 105.48% from the prior year.
• Other Non Operating Income declined to $212000.0 in Q1 2026, from $247000.0 in the prior quarter.
• In the past five years, Other Non Operating Income ranged from a high of $2.1 million in Q1 2023 to a low of -$6.9 million in Q4 2023.
• A 5-year average of -$1.5 million and a median of -$929000.0 in 2024 frame the typical range for Other Non Operating Income.
• Across the five-year window, Other Non Operating Income tumbled 651.22% in 2022 and jumped 130.43% in 2026, its largest moves.
• Tracing ALLO's Other Non Operating Income over 5 years: stood at -$3.6 million in 2022, then sank by 90.65% to -$6.9 million in 2023, then jumped by 71.85% to -$2.0 million in 2024, then jumped by 112.65% to $247000.0 in 2025, then declined by 14.17% to $212000.0 in 2026.
• Business Quant data shows ALLO's Other Non Operating Income at $212000.0 in Q1 2026, $247000.0 in Q4 2025, and -$81000.0 in Q3 2025.